E-LIB Suche - Ergebnisse für: O'Hara, Mark H.

1

Combining antivascular endothelial growth factor and anti-e..:

Hochster, Howard S ; Catalano, Paul ; Weitz, Michelle...
JNCI: Journal of the National Cancer Institute. 116 (2024) 9 - p. 1487-1494 , 2024

Link: https://doi.org/10.1093/..

2

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entin..:

Karasic, Thomas B ; Brown, Timothy J ; Schneider, Charles...
The Oncologist. 27 (2022) 9 - p. 716-e689 , 2022

Link: https://doi.org/10.1093/..

3

Sotigalimab and/or nivolumab with chemotherapy in first-lin..:

Padrón, Lacey J. ; Maurer, Deena M. ; O'Hara, Mark H....
Nature Medicine. 28 (2022) 6 - p. 1167-1177 , 2022

Link: https://doi.org/10.1038/..

4

Correction: THBS2 as a prognostic biomarker for patients di..:

Gimotty, Phyllis A. ; Till, Jacob E. ; Udgata, Shirsa...
Oncotarget. 13 (2022) 1 - p. 1187-1187 , 2022

Link: https://doi.org/10.18632..

5

Biochemical and functional characterization of mutant KRAS ..:

Bear, Adham S. ; Blanchard, Tatiana ; Cesare, Joseph...
Nature Communications. 12 (2021) 1 - p. , 2021

Link: https://doi.org/10.1038/..

6

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces..:

Byrne, Katelyn T. ; Betts, Courtney B. ; Mick, Rosemarie...
Clinical Cancer Research. 27 (2021) 16 - p. 4574-4586 , 2021

Link: https://doi.org/10.1158/..

7

THSB2 as a prognostic biomarker for patients diagnosed with..:

Gimotty, Phyllis A. ; Till, Jacob E. ; Udgata, Shirsa...
Oncotarget. 12 (2021) 22 - p. 2266-2272 , 2021

Link: https://doi.org/10.18632..

8

An NK-like CAR T cell transition in CAR T cell dysfunction:

Good, Charly R. ; Aznar, M. Angela ; Kuramitsu, Shunichiro...
Cell. 184 (2021) 25 - p. 6081-6100.e26 , 2021

Link: https://doi.org/10.1016/..

9

Comparative Effectiveness of Total Neoadjuvant Therapy Vers..:

Yu, Shun ; Mamtani, Ronac ; O'Hara, Mark H....
Clinical Colorectal Cancer. 20 (2021) 2 - p. 121-129 , 2021

Link: https://doi.org/10.1016/..

10

Combining Radiation with Immunotherapy: The University of P..:

Luo, Leo Y. ; O'Hara, Mark H. ; Mitchell, Tara C....
Seminars in Radiation Oncology. 30 (2020) 2 - p. 173-180 , 2020

Link: https://doi.org/10.1016/..

11

Phase II Trial of Palbociclib in Patients with Advanced Eso..:

Karasic, Thomas Benjamin ; O'Hara, Mark H. ; Teitelbaum, Ursina R....
The Oncologist. 25 (2020) 12 - p. e1864-e1868 , 2020

Link: https://doi.org/10.1634/..

12

Dual Targeting of Mesothelin and CD19 with Chimeric Antigen..:

Ko, Andrew H. ; Jordan, Alexander C. ; Tooker, Evan...
Molecular Therapy. 28 (2020) 11 - p. 2367-2378 , 2020

Link: https://doi.org/10.1016/..

13

Early treatment-related neutropenia predicts response to pa..:

McAndrew, Nicholas P. ; Dickson, Mark A. ; Clark, Amy S....
British Journal of Cancer. 123 (2020) 6 - p. 912-918 , 2020

Link: https://doi.org/10.1038/..

14

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY..:

O'Hara, Mark H. ; Messersmith, Wells ; Kindler, Hedy...
Journal of Pancreatic Cancer. 6 (2020) 1 - p. 21-31 , 2020

Link: https://doi.org/10.1089/..

15

Phase I Study of Lentiviral-Transduced Chimeric Antigen Rec..:

Haas, Andrew R. ; Tanyi, Janos L. ; O'Hara, Mark H....
Molecular Therapy. 27 (2019) 11 - p. 1919-1929 , 2019

Link: https://doi.org/10.1016/..